BH3 mimetics to improve cancer therapy; mechanisms and examples
| Autor: | Lihua Ming, Lin Zhang, Jian Yu |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Cancer Research
Bh3 mimetic Molecular Sequence Data bcl-X Protein Cancer therapy Antineoplastic Agents Apoptosis Tumor cells Computational biology Biology Bioinformatics Piperazines Article Nitrophenols Neoplasms Animals Humans Bcl x protein Pharmacology (medical) Amino Acid Sequence Peptide sequence Pharmacology Sulfonamides Bh3 mimetics Biphenyl Compounds Drugs Investigational Small molecule Neoplasm Proteins Protein Structure Tertiary Biphenyl compound Treatment Outcome Infectious Diseases Proto-Oncogene Proteins c-bcl-2 Oncology Drug Resistance Neoplasm Myeloid Cell Leukemia Sequence 1 Protein biological phenomena cell phenomena and immunity Sequence Alignment |
| Zdroj: | Drug Resistance Updates. 10:207-217 |
| ISSN: | 1368-7646 |
| DOI: | 10.1016/j.drup.2007.08.002 |
| Popis: | Tumor cell survival is highly dependent on the expression of certain pro-survival Bcl-2 family proteins. An attractive therapeutic approach is to inhibit these proteins using agents that mimic the Bcl-2 homology 3 (BH3) domains of the proapoptotic Bcl-2 family members, which neutralize these proteins by binding to their surface hydrophobic grooves. A number of BH3 mimetic peptides and small molecules have been described, a few of which have advanced into clinical trials. Recent studies have highlighted ABT-737, a bona fide BH3 mimetic and potent inhibitor of antiapoptotic Bcl-2 family members, as a promising anticancer agent. This review summarizes recent advances in understanding the mechanisms of action of BH3 domains and several classes of BH3 mimetics, as well as the prospects of using these agents to improve cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect